AnaptysBio (STU:AN6) E10: €-2.87 (As of Mar. 2026)


STU:AN6 AnaptysBio Inc STU:AN6
67 GF Score
Price €51.24
GF Value €54.21
! 3 Warning Signs
View Full Analysis

What is AnaptysBio E10?

AnaptysBio STU:AN6 -1.20% 67 E10 is €-2.87 as of Mar. 2026. GuruFocus rates STU:AN6 with a GF Score™ of 67/100 and a GF Value™ of €54.21. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AnaptysBio's adjusted earnings per share data for the three months ended in Mar. 2026 was €-1.592. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-2.87 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), AnaptysBio's current stock price is €51.24. AnaptysBio's E10 for the quarter that ended in Mar. 2026 was €-2.87. AnaptysBio's Shiller PE Ratio of today is .


AnaptysBio  (STU:AN6) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AnaptysBio E10 Related Terms


AnaptysBio E10 Historical Data

* Premium members only.

The historical data trend for AnaptysBio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio E10 Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.78 -2.72

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.93 -2.80 -2.09 -2.72 -2.87

STU:AN6 vs VIR, GHRS, INVA: E10 Comparison

For the Biotechnology subindustry, AnaptysBio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Shiller PE Ratio falls into.


STU:AN6
67GF Score
AnaptysBio Inc STU:AN6
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AnaptysBio's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.592/330.2130*330.2130
=-1.592

Current CPI (Mar. 2026) = 330.2130.

AnaptysBio Quarterly Data

per share eps CPI Adj_EPS
201606 0.011 241.018 0.015
201609 -0.070 241.428 -0.096
201612 -0.222 241.432 -0.304
201703 -0.701 243.801 -0.949
201706 -0.116 244.955 -0.156
201709 -0.378 246.819 -0.506
201712 -0.253 246.524 -0.339
201803 -0.511 249.554 -0.676
201806 -0.488 251.989 -0.639
201809 -0.566 252.439 -0.740
201812 -0.563 251.233 -0.740
201903 -0.726 254.202 -0.943
201906 -0.788 256.143 -1.016
201909 -1.044 256.759 -1.343
201912 -0.675 256.974 -0.867
202003 -0.271 258.115 -0.347
202006 -0.702 257.797 -0.899
202009 -0.739 260.280 -0.938
202012 1.011 260.474 1.282
202103 -0.554 264.877 -0.691
202106 -0.017 271.696 -0.021
202109 -0.204 274.310 -0.246
202112 -1.044 278.802 -1.237
202203 -1.189 287.504 -1.366
202206 -1.088 296.311 -1.212
202209 -1.192 296.808 -1.326
202212 -0.878 296.797 -0.977
202303 -1.476 301.836 -1.615
202306 -1.385 305.109 -1.499
202309 -1.321 307.789 -1.417
202312 -1.458 306.746 -1.570
202403 -1.509 312.332 -1.595
202406 -1.589 314.175 -1.670
202409 -1.027 315.301 -1.076
202412 -0.688 315.605 -0.720
202503 -1.184 319.799 -1.223
202506 -1.162 322.561 -1.190
202509 0.443 324.800 0.450
202512 1.349 324.054 1.375
202603 -1.592 330.213 -1.592

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-2.87 mean?
AnaptysBio (STU:AN6) has a E10 of €-2.87 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AnaptysBio and its competitors.
Is AnaptysBio's E10 too high?
AnaptysBio's current E10 is €-2.87. Overall, AnaptysBio has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's E10 compare to VIR and GHRS?
AnaptysBio's E10 of €-2.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AnaptysBio and its competitors. AnaptysBio's current E10 is €-2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
AnaptysBio (STU:AN6) has a current E10 of €-2.87. The stock's GF Value™ is €54.21, compared to a current price of €51.24 — trading 5.5% below its estimated fair value. The current E10 is €-2.87. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For AnaptysBio (STU:AN6), the current E10 is €-2.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (STU:AN6) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of €51.24 is trading 5.5% below its estimated GF Value™ of €54.21.

Key valuation signals for STU:AN6:

  • E10: €-2.87
  • GF Value™: €54.21 vs. price of €51.24 (5.5% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the STU:AN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AnaptysBio Business Description

Other Exchanges ANAB:USA0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for STU:AN6

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.24
Price
€54.21
GF Value